Plecanatide (Trulance) for chronic idiopathic constipation and irritable bowel syndrome with constipation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5871240 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Assessing real-world safety of plecanatide: a pharmacovigilance study based on the FDA adverse event reporting system.
Front Pharmacol
November 2024
The Second Clinical College of Dalian Medical University, Dalian Medical University, Dalian, Liaoning, China.
Article Synopsis
- Plecanatide is a gastro-peptide used to treat chronic constipation and IBS with constipation, and this study aimed to evaluate its long-term safety in real-world scenarios.
- Data from the FDA Adverse Event Reporting System between 2017 and 2024 revealed 861 cases and 2057 adverse event reports, with diarrhea and abdominal issues being common side effects.
- The study suggests that most adverse events occur within the first week of treatment and provides critical safety insights for healthcare providers prescribing plecanatide.
A real-world study of persistence and adherence to prescription medications in patients with chronic idiopathic constipation in the United States.
J Manag Care Spec Pharm
October 2024
Atrium Health Wake Forest Medical University, Charlotte, NC.
Background: At present, 4 prescription therapies have been approved by the US Food and Drug Administration for the treatment of chronic idiopathic constipation (CIC) in adults.
Objectives: To compare persistence with and adherence to prucalopride vs 3 other prescription medications for CIC in a US population.
Methods: This retrospective, observational cohort study used data from the IBM MarketScan Commercial Claims and Encounters and Medicare Supplemental Databases (January 2015-June 2020).
Review of the Patient Burden and Therapeutic Landscape of Irritable Bowel Syndrome with Constipation in the United States.
Clin Exp Gastroenterol
August 2024
Division of Gastroenterology, Advocate Health Wake Forest Medical University, Charlotte, NC, USA.
Irritable bowel syndrome (IBS) is a common disorder of the gut-brain axis. IBS with constipation (IBS-C) accounts for approximately one-third of IBS cases and is associated with substantial burden of illness and decreased quality of life. This narrative review provides an overview of the current and upcoming treatment options and disease management for IBS-C from a US perspective and discusses the importance of the relationship between patient and health care provider in diagnosis and treatment.
View Article and Find Full Text PDFCurrent and future pharmacotherapies for the management of constipation-predominant irritable bowel syndrome.
Expert Opin Pharmacother
June 2024
Department of Biochemistry, Faculty of Medicine, Medical University of Lodz, Lodz, Poland.
Article Synopsis
- Irritable bowel syndrome (IBS) affects 9-23% of people globally, particularly women, and is influenced by various psychosocial and physiological factors, often worsening with stress.
- The most common type of IBS is IBS-C, leading to the development of new treatments like linaclotide and dietary changes, such as higher fiber and low FODMAP foods, to alleviate symptoms.
- Experts stress the need for effective treatments as IBS-C significantly impacts quality of life, suggesting potential in multi-drug therapies and further dietary interventions for patients.
Plecanatide Improves Abdominal Bloating and Bowel Symptoms of Irritable Bowel Syndrome with Constipation.
Dig Dis Sci
May 2024
Division of Gastroenterology and Department of Psychiatry, Washington University School of Medicine, St. Louis, MO, USA.
Background: Bloating is a bothersome symptom in irritable bowel syndrome with constipation (IBS-C).
Aim: To evaluate plecanatide efficacy in patients with IBS-C stratified by bloating intensity.
Methods: Pooled phase 3 data (2 randomized, controlled IBS-C trials) from adults treated with plecanatide 3 mg or placebo for 12 weeks were analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!